Scholtz & Company’s Celgene Corp CELG Stock Holding History

Scholtz & Company’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-26,265	Closed	-$3.83M	–	78
2017 Q3	$3.83M	Buy	26,265 +16,290	+163%	+$2.22M	3%	14
2017 Q2	$1.29M	Buy	+9,975	New	+$1.22M	1.12%	39

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Scholtz & Company's CELG Position: Q4 2017 in Review

Scholtz & Company sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 26,265 shares — an estimated $3.83M sold.

Scholtz & Company first reported a position in CELG in Q2 2017 and held it in 2 quarters. The position peaked at $3.83M in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

Scholtz & Company reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
Scholtz & Company sold 26,265 Celgene Corp shares in Q4 2017, an estimated $3.83M.
Scholtz & Company first reported a position in Celgene Corp in Q2 2017 and held it in 2 quarters.
Scholtz & Company's Celgene Corp position peaked at $3.83M in Q3 2017.
1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Scholtz & Company's 13F filing for Q4 2017, filed 14 Feb 2018.